{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:55:47Z","timestamp":1792540547142,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejca.2026.116879","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T18:21:12Z","timestamp":1781461272000},"page":"116879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Outcomes of CAR T\u2010Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study"],"prefix":"10.1016","volume":"244","author":[{"given":"Nicole","family":"Fabbri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4453-6064","authenticated-orcid":false,"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2977-0098","authenticated-orcid":false,"given":"Annalisa","family":"Chiappella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Donzelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Musso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Angelillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3721-0004","authenticated-orcid":false,"given":"Ilaria","family":"Cutini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1035-4972","authenticated-orcid":false,"given":"Paolo","family":"Rivela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-9054","authenticated-orcid":false,"given":"Alessia","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7280-2040","authenticated-orcid":false,"given":"Mauro","family":"Krampera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Petruzzellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Grillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116879_bib1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41408-024-01194-5","article-title":"A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study","volume":"14","author":"Vaughn","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ejca.2026.116879_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.seminhematol.2023.11.002","article-title":"DLBCL arising from indolent lymphomas: how are they different?","volume":"60","author":"Parry","year":"2023","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ejca.2026.116879_bib3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjh.14831","article-title":"Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group","volume":"178","author":"Alonso-\u00c1lvarez","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2026.116879_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clml.2022.09.003","article-title":"Risk factors for and outcomes of follicular lymphoma histological transformation at first progression in the GALLIUM study","volume":"23","author":"Casulo","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ejca.2026.116879_bib5","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1200\/JCO.18.00138","article-title":"Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution","volume":"36","author":"Alderuccio","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116879_bib6","unstructured":"NCCN Guidelines Version 2.2025."},{"key":"10.1016\/j.ejca.2026.116879_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116879_bib8","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022018893","article-title":"5-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1)","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.116879_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116879_bib10","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116879_bib11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116879_bib12","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-148948","article-title":"Two-year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R\/R) large B-cell lymphomas (LBCL)","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.116879_bib13","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.116879_bib14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116879_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/hematology.2023000436","article-title":"CAR T-cell therapy in aggressive lymphomas\u2014identifying prognostic and predictive markers","volume":"2023","author":"Mussetti","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.ejca.2026.116879_bib16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116879_bib17","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116879_bib18","unstructured":"P. Stephan, R. Blasi, L. Roulin, et al., Transcar: a real-life out- come study of relapsed\/refractory transformed indolent non-hodgkin lymphoma in the context of CAR T Cells: a DESCART analysis 8, e104 (EHA2024 Hybrid Congress: HemaSphere, 2024), https:\/\/doi.org\/10. 1002\/hem3.104."},{"key":"10.1016\/j.ejca.2026.116879_bib19","article-title":"Clinical outcomes of transformed follicular lymphoma with CAR T-cell therapy: a US multicenter real-world analysis","volume":"144","author":"Cortese","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.116879_bib20","article-title":"Outcomes of CD19 CAR T in transformed indolent lymphoma compared to de novo aggressive large B-cell lymphoma","author":"Thiruvengadam","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2026.116879_bib21","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-187379","article-title":"Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy","volume":"142","author":"Rivas-Delgado","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.116879_bib22","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-154459","article-title":"Safety and short-term efficacy of CART cells in treatment of diffuse large B-cell lymphoma with follicular transformation","volume":"138","author":"Hu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.116879_bib23","unstructured":"Yescarta, summary of product characteristics.pdf."},{"key":"10.1016\/j.ejca.2026.116879_bib24","unstructured":"Kymriah, summary of product characteristics.pdf."},{"key":"10.1016\/j.ejca.2026.116879_bib25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2026.116879_bib26","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.116879_bib27","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.116879_bib28","series-title":"Stata Statistical Software: Release 17","author":"StataCorp","year":"2023"},{"key":"10.1016\/j.ejca.2026.116879_bib29","unstructured":"R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. RL https:\/\/www.R-project.org\/."},{"key":"10.1016\/j.ejca.2026.116879_bib30","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116879_bib31","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.3390\/cancers13236073","article-title":"Transformed lymphoma is associated with a favorable response to CAR-T-cell treatment in DLBCL patients","volume":"13","author":"Nydegger","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2026.116879_bib32","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600660X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600660X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:13:14Z","timestamp":1787112794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492600660X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"alternative-id":["S095980492600660X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116879","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of CAR T\u2010Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116879","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116879"}}